Oxford Biomedica PLC Oxford BioMedica further capacity expansion (6194A)
September 13 2018 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 6194A
Oxford Biomedica PLC
13 September 2018
Oxford BioMedica announces further capacity expansion with new
facility
- Lentiviral vector bioprocessing market expected to grow to $800m by 2026
- Oxford BioMedica adds fourth facility in Oxford allowing the
Group to target 25% to 30% of global lentiviral vector
bioprocessing market (excluding milestones and royalties)
Oxford, UK - 13 September 2018: Oxford BioMedica plc (LSE:OXB)
("Oxford BioMedica" or "the Group"), a leading gene and cell
therapy group, today announces that it has signed a fifteen year
lease on a new facility in Oxford that is close to its Windrush
Court headquarters.
The new facility is approx. 84,000 sqft (7,800 sqm). The Group's
planned Phase I and Phase 2 expansion will fit out around 45,000
sqft (4,200 sqm) for four GMP clean room suites and two fill and
finish suites as well as offices, warehousing and QC laboratories,
with space available for future expansion. Once open, the facility
will more than double the Group's bioprocessing capacity. The plan
is to open the new offices and warehouse in Q1 2019, with the
additional GMP suites being ready in Q1 2020.
This new full-service site, fully funded through the successful
Placing in March 2018, will allow the Group to exploit the
immediate market opportunity, meet the expected long-term demand
and futureproof Oxford BioMedica's market leading position. This
new facility secures Oxford as a bioprocessing centre for Oxford
BioMedica and will create up to 100 new, highly skilled positions
at the Group over the next two years.
John Dawson, Chief Executive Officer of Oxford BioMedica, said:
"We are delighted to secure this new facility in Oxford for our
capacity expansion programme. Oxford BioMedica is a leading gene
and cell therapy Group and, following the approval of the first
gene therapy in the US, we have seen a step change in business
development enquiries for our expertise across the LentiVector(TM)
enabled platform. With the finances secured earlier this year, we
are now able to accelerate our investment in the new facility
which, once on stream, will have the capacity to meet the expected
long-term demand for lentiviral vectors."
-Ends-
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Financial and corporate communications Tel: +44 (0)20 3709 5700
enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Olivia
Manser/Laura Thornton
Notes to editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene
Therapy Consortium/Imperial Innovations, GC LabCell and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
320 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDSFAESEFASELU
(END) Dow Jones Newswires
September 13, 2018 02:00 ET (06:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024